DE602005017373D1 - Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten - Google Patents

Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten

Info

Publication number
DE602005017373D1
DE602005017373D1 DE602005017373T DE602005017373T DE602005017373D1 DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1 DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1
Authority
DE
Germany
Prior art keywords
gluco
compounds
treating schizophrenia
regulatory conditions
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017373T
Other languages
English (en)
Inventor
Craig P Smith
David E Rampe
Beth Borowsky
Sathapana Kongsamut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE602005017373D1 publication Critical patent/DE602005017373D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005017373T 2004-04-01 2005-04-01 Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten Active DE602005017373D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
PCT/US2005/011107 WO2005097122A2 (en) 2004-04-01 2005-04-01 Method of treating schizophrenia and/or glucoregulatory abnormalities

Publications (1)

Publication Number Publication Date
DE602005017373D1 true DE602005017373D1 (de) 2009-12-10

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017373T Active DE602005017373D1 (de) 2004-04-01 2005-04-01 Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten

Country Status (26)

Country Link
US (1) US20070129403A1 (de)
EP (2) EP2138176A1 (de)
JP (1) JP2007531730A (de)
KR (1) KR20070010161A (de)
CN (1) CN1946399A (de)
AR (1) AR048197A1 (de)
AT (1) ATE446754T1 (de)
AU (1) AU2005231446A1 (de)
BR (1) BRPI0509512A (de)
CA (1) CA2561162A1 (de)
CL (1) CL2009001605A1 (de)
CY (1) CY1109734T1 (de)
DE (1) DE602005017373D1 (de)
DK (1) DK1734959T3 (de)
DO (1) DOP2005000050A (de)
ES (1) ES2334241T3 (de)
GT (1) GT200500063A (de)
IL (1) IL178168A0 (de)
MX (1) MXPA06011222A (de)
PA (1) PA8628601A1 (de)
PL (1) PL1734959T3 (de)
PT (1) PT1734959E (de)
SI (1) SI1734959T1 (de)
SV (1) SV2006002069A (de)
TW (1) TW200602040A (de)
WO (1) WO2005097122A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (de) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Verwendung von spiro-oxindol-verbindungen als therapeutika
CN106928247A (zh) 2008-10-17 2017-07-07 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
EP2350091B1 (de) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindol verbindungen und ihre verwendung als therapeutische wirkstoffe
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
CA3151507C (en) 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN113840569A (zh) * 2019-03-19 2021-12-24 剑桥认知有限公司 诊断精神病症和推荐用于精神病症的治疗的方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
CN1184969C (zh) * 1995-07-27 2005-01-19 阿温蒂斯药物公司 未取代和取代的n-(吡咯-1-基)吡啶胺作为抗惊厥药的用途
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
EP1826216A1 (de) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1-Derivate
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
BRPI0509512A (pt) 2007-09-11
AU2005231446A1 (en) 2005-10-20
TW200602040A (en) 2006-01-16
EP2138176A1 (de) 2009-12-30
WO2005097122A3 (en) 2006-02-02
SV2006002069A (es) 2006-05-24
ATE446754T1 (de) 2009-11-15
CY1109734T1 (el) 2014-09-10
GT200500063A (es) 2005-10-14
CL2009001605A1 (es) 2009-11-27
DK1734959T3 (da) 2010-03-08
PL1734959T3 (pl) 2010-03-31
KR20070010161A (ko) 2007-01-22
JP2007531730A (ja) 2007-11-08
WO2005097122A2 (en) 2005-10-20
DOP2005000050A (es) 2005-11-30
EP1734959B1 (de) 2009-10-28
AR048197A1 (es) 2006-04-05
MXPA06011222A (es) 2007-01-16
SI1734959T1 (sl) 2010-02-26
EP1734959A2 (de) 2006-12-27
PT1734959E (pt) 2009-12-24
CA2561162A1 (en) 2005-10-20
US20070129403A1 (en) 2007-06-07
CN1946399A (zh) 2007-04-11
PA8628601A1 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE509615T1 (de) Verfahren und zusammensetzungen zur verhütung und/oder zur behandlung von empfindlicher und/oder trockener haut
ATE496911T3 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
DE602005023452D1 (de) Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602004010705D1 (de) Vorrichtung und Verfahren zur Behandlung von Mist enthaltendem Abwasser
DE602005010222D1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
DE60321938D1 (de) Zusammensetzung zur schleimvermeidung und verfahren zur schleimvermeidung
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
ATE328880T1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition